Shares of Nephros, Inc. (OTCMKTS:NEPH) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.08 and traded as low as $5.90. Nephros shares last traded at $6.28, with a volume of 17,400 shares.
Several analysts have commented on NEPH shares. Zacks Investment Research raised shares of Nephros from a “hold” rating to a “strong-buy” rating and set a $9.50 target price for the company in a research note on Thursday, March 12th. Maxim Group restated a “buy” rating and set a $16.00 target price on shares of Nephros in a report on Saturday, February 29th.
The firm’s 50 day moving average is $8.02 and its two-hundred day moving average is $8.66. The firm has a market cap of $61.52 million, a P/E ratio of -11.62 and a beta of 0.85. The company has a current ratio of 2.56, a quick ratio of 1.86 and a debt-to-equity ratio of 0.26.
A number of hedge funds and other institutional investors have recently modified their holdings of NEPH. Millennium Management LLC bought a new position in Nephros in the 3rd quarter worth about $313,000. Ingalls & Snyder LLC grew its stake in Nephros by 104.5% in the fourth quarter. Ingalls & Snyder LLC now owns 134,539 shares of the company’s stock worth $1,339,000 after purchasing an additional 68,750 shares during the period. Finally, Parkman Healthcare Partners LLC purchased a new stake in Nephros in the fourth quarter worth $1,987,000.
Nephros Company Profile (OTCMKTS:NEPH)
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.